Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement To Evaluate a Novel Device To Improve Patient Experience and Access to Neurological Aso Therapies
Biogen Inc. and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRxTM System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreement, Biogen aims to leverage the ThecaFlex DRxTM System with a goal of improving the patient treatment experience and accessibility for a broader population of people suffering from neurological disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
From Fighting Shoplifting to Pioneering Gene Therapies, the Startups in This Accelerator Are on the Front Lines of “Super Creativity”
The startups within UF Innovate, as well as the accelerator itself, are vivid examples of what creativity and innovation expert James Taylor, based in Scotland, describes as SuperCreativity—a phenomenon that many business leaders are trying to foster in today’s fast-changing business environment. It is a concept that goes beyond creativity or innovation alone.
TearClear Announces Positive Topline Results From Clear Phase 3 Study for the Treatment of Glaucoma
TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced that the company’s will file a NDA with the FDA on their lead product. This product will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.
Concept Companies and Lacerta Therapeutics Form a Strategic Partnership Around Facilities Expansion and Financing
Concept Companies, a national commercial real estate developer with a specialty across multiple asset classes including science and technology, and Lacerta Therapeutics, Inc., a leader in the AAV gene therapy space, today announced a strategic collaboration providing Lacerta with access to financing to support expansion of operations and new facilities. The financing is being provided via Agility Venture Capital, the funding arm of Concept Companies.
Lacerta and Prevail, a Wholly Owned Subsidiary of Lilly, Sign Agreement To Develop Novel AAV Capsids for CNS Disorders
Lacerta Therapeutics, a leader in the development of adeno-associated virus (AAV) technologies for the treatment of central nervous system (CNS) diseases, announced a new AAV capsid licensing and research collaboration agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.
UF Accelerate Residents Announced As Finalists for the 12th Annual GrowFL Florida Companies To Watch
UF Accelerate | Sid Martin Biotech resident Neobiosis, and UF Accelerate | The Hub resident Quottly, have been selected as finalists for this year’s annual GrowFL Florida companies to watch.
The Emerging Field of Regenerative Medicine: Personalized, Precision Medicine
Regenerative medicine, in conjunction with personalized medicine, is responsible for the next major paradigm shift in modern medicine. However, neither regenerative nor personalized precision medicine are subjects traditionally found in the curriculum of U.S. medical schools. As such, this emergence has been met with skepticism, doubt and confusion.
Morphogenesis Gets Closer to a Cancer Vaccine
UF Startup and Sid Martin graduate company Morphogenesis, says it is getting closer to a shot that would treat some skin cancers.
CEO of UF Startup AxoGen is appointed to EyePoint Pharmaceuticals Board of Directors
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its Board of Directors. Ms. Zaderej is currently the President, Chief Executive Officer and Chair of the Board at UF Startup and Accelerate graduate AxoGen, Inc., and brings more than 35 years of biopharmaceutical and medical device experience to the role.
What Does a Dog’s Nose Know? A.I. May Soon Tell Us
UF Accelerate client Canaery, thinks it can read the neurons firing in a dog’s olfactory bulb in real-time and, with the help of machine learning, turn the animal into a detection device able to suss out a vast range of molecules, all without the animal having to be specially trained. “This does for scent what machine vision did for sight,” says Gabriel Lavella, Canaery’s founder and chief executive officer.